CeeNU (Lomustine) supply in Canada: Notice

On this page

Background

Lomustine is used as palliative therapy in patients with brain tumours, Hodgkin's Disease and other tumours.

Lomustine was previously marketed in Canada by Bristol Myers Squibb (BMS) under the brand name CeeNU in 10 mg and 40 mg capsules. As of June 29, 2026, Septa Pharmaceuticals acquired the rights to market the drug in Canada. A market launch date is not yet available.

What we are doing

We recognize the importance of continued access to lomustine for patients in Canada.

We have allowed Septa Pharmaceuticals to import US-authorized lomustine in 10 mg and 40 capsules and UK-authorized lomustine in 40 mg capsules until December 2026. Visit the List of Drugs for Exceptional Importation and Sale for more details.

We are also communicating with provincial and territorial governments and other stakeholders, such as the Brain Tumour Foundation of Canada, to coordinate the sharing of information about this drug.

What you can do

Speak with your doctor or pharmacist if you have questions or concerns about the discontinuation of lomustine. They may be able to offer other options if your medicine is not available.

You should always:

Report any health product-related side effects or complaints to Health Canada.

Learn more about drug shortages in Canada and how Canadians can deal with drug shortages.

Related links

Page details

2026-09-11